Persistent stiffness, weakness on the stairs, and a dull ache from cartilage wear that limits everyday movement.
Painkillers, hyaluronic acid, or PRP may ease symptoms, but relief is often short-lived and the pain returns.
Not yet a candidate for joint replacement, and looking for a less invasive option before considering major surgery.
Mytocel™ MSK is an autologous (using your own tissue), minimally invasive treatment for the knee, built on AMT® — Autologous Micrografting Technology®. A small sample of your own cartilage, taken from behind the ear, is processed by the European-patented Rigenera® device into an injectable AMT® Solution — tiny grafts of about 80 microns (µm) that keep the tissue's natural support structure intact, with up to 90% of cells kept alive and active.
Each micrograft solution combines three core elements:
"Delivered into the affected joint, the AMT® Solution aims to optimise the local repair environment — helping to ease inflammation and support cartilage restoration."
A discreet spot behind the ear is numbed under local anaesthesia, so the sample collection is comfortable and virtually pain-free.
A tiny cartilage sample (about 2.5 mm) is taken from behind the ear. The site is small enough to need no stitches and typically heals within about 7 days, leaving no visible mark.
The sample is placed in the patented Rigenera® device, which gently breaks the tissue down by mechanical action into an injectable AMT® Solution — no chemicals and no cell culture, so your own biological material is preserved.
The AMT® Solution is injected directly into the affected joint to support its own repair process. No hospital stay is needed — most patients walk out and get back to daily activities the same day.
The Rigenera® technology behind Mytocel™ MSK is developed by Human Brain Wave (HBW) in Italy and supported by 80 international publications.
In a published pilot study, average VAS pain scores fell by 71%, with relief often noted within a few weeks.
Mean KOOS (Knee Injury and Osteoarthritis Outcome Score) improved by 80% in the same study.
A separate study reported pain improvement maintained at 3 years, alongside imaging signs of cartilage change.
Sourced and used within the same patient, with no chemical additives; no serious adverse events reported in studies.
* Figures are drawn from Human Brain Wave (HBW) clinical publications and observational studies. Individual results and duration vary with each patient's overall health, age, degree of degeneration, and lifestyle.
A less invasive, autologous approach to consider before joint replacement surgery.
* Suitability depends on a specialist's clinical assessment of the degree of degeneration (e.g. Kellgren–Lawrence grade); not all stages are suitable for this procedure. This table is provided for general reference only.
Mytocel™ MSK is a minimally invasive protocol for joint restoration based on AMT® (Autologous Micrografting Technology®). A small cartilage sample from behind your ear is processed with the patented Rigenera® device into an injectable micrograft solution, then delivered into the affected joint to support your body's own repair mechanism.
* Note: this protocol is intended to support the joint's repair environment. It does not replace severely worn cartilage and is not a guaranteed cure; suitability and outcomes must be assessed by a doctor.
No. Mytocel™ MSK is a non-surgical, minimally invasive procedure performed in-clinic under local anaesthesia. From micro-biopsy to injection, it takes about 30–45 minutes. The collection site is roughly 2.5 mm, needs no stitches, and you can walk out the same day with no hospital stay.
The procedure is done under local anaesthesia, so discomfort during treatment is minimal. Mild swelling or soreness at the collection and injection sites is common and usually settles within a few days. There is no lengthy downtime, and most patients resume basic daily activities the same day. We recommend avoiding strenuous exercise and heavy loading for 1–2 weeks after treatment.
In clinical observation, many patients notice reduced pain and improved joint mobility within about 2 to 4 weeks; some studies report improvement as early as 3 weeks. Because the aim is to support your own repair process, benefits can be longer-lasting — one study observed pain improvement maintained at 3 years. Actual results vary with individual degree of degeneration and lifestyle.
Yes — it must be carried out by a registered medical practitioner in a licensed clinic.
Under Hong Kong's Medical Registration Ordinance (Cap. 161) and Private Healthcare Facilities Ordinance (Cap. 633), RGA / AMT involves local anaesthesia, minimally invasive autologous tissue harvesting, and injection, and is strictly defined as a medical procedure.
The law requires this treatment to be performed personally by a Hong Kong registered medical practitioner in a licensed clinic with sterile facilities. Ordinary beauty salons and non-medical establishments may not legally perform it. All Joy Med treatments are carried out by qualified doctors in a sterile clinical setting, in line with the highest medical safety standards.
